Cassava Sciences, Inc.

NASDAQ:SAVAHealthcare · Biotechnology

Mkt Cap-

Float42.98M

Shares O/S-

Inst Own-

Dilution

Mkt Cap-

Float42.98M

O/S-

Inst Own-

Dilution

NASDAQ:SAVA

MCap-

Float42.98M

O/S-

Inst Own-

Dilution

Historical Data

Date	Open	High	Low	Close	Volume

Key Metrics

Market Cap--

Enterprise Value--

P/E Ratio--

Est. Net Cash/Share--

Institutional Ownership--

SectorHealthcare

IndustryBiotechnology

ExchangeNASDAQ

Country

IPO DateJul 14, 2000

Shares Outstanding-

Float42.98M

Company Overview

Cassava Sciences, Inc. is a biopharmaceutical enterprise in the clinical development phase, specializing in the creation of treatments for neurodegenerative disorders.

The company's primary experimental drug, simufilam, a small-molecule compound, has successfully concluded its Phase 2b clinical trials. In parallel, they are advancing SavaDx, an investigational blood-based biomarker test designed to aid in the detection of Alzheimer's disease. Established in 1998 and headquartered in Austin, Texas, the company underwent a name change in March 2019, previously operating as Pain Therapeutics, Inc.

Leadership

Claude Nicaise, M.D.

Chairman of the Board of Directors

Eric J. Schoen

Chief Financial Officer

Freda Nassif

Chief Business Officer & Chief Commercial Officer

James W. Kupiec, M.D.

Chief Medical Officer

Employees

Country

Sector

Healthcare

Website

cassavasciences.com

Analyst Coverage

ConsensusBuy

Price Target

No price targets available

Ratings Distribution

BUY

HOLD

SELL

TOTAL12

Insider Trades

Insider	Title	Type	Shares	Value	Date
Anderson Robert Eugene Jr	Director	Purchase	8.6K	$24.9K	Nov 24, 2025
Barry Richard	President & CEO	Purchase	150.0K	$414.0K	Nov 20, 2025
Barry Richard	President & CEO	Purchase	73.4K	$201.8K	Nov 19, 2025
Bir Dawn Carter	Director	Grant/Award	53.0K	--	Oct 21, 2025
Cook Robert Christopher	SVP & General Counsel	Purchase	13.7K	$39.9K	Sep 30, 2025
Barry Richard	President & CEO	Purchase	7.2K	$16.4K	Sep 22, 2025

Shareholders

Institutional

(85)

Insiderⓘ

(3)

5%+ Owners

(2)

Unattributed (incl. retail)ⓘ

Top Shareholders

Name	Shares	%	Source
Nachtrab Matthew · may incl. warrants· filed Nov 2024	2.3M	4.7%	13G
The Vanguard Group · filed Jul 2025	2.2M	4.5%	13G
Remi Barbier · may incl. warrants· filed Nov 2024	2.1M	4.2%	13G
VANGUARD CAPITAL MANAGEMENT LLC	2.0M	--	13F
TWO SIGMA INVESTMENTS, LP	1.7M	--	13F
MARSHALL WACE, LLP	1.6M	--	13F
BlackRock, Inc. · also on 13F· may incl. warrants· filed Jul 2025	1.5M	3.2%	13G
BlackRock, Inc.	1.5M	--	13F
GOLDMAN SACHS GROUP INC	668.8K	--	13F
GEODE CAPITAL MANAGEMENT, LLC	615.5K	--	13F